Chronic Lyme and the peptide conversation
9 min read · Uplevel editorial
You finished the antibiotics. Your doctor said you were treated. The test came back negative, or the titer was low, technically borderline, interpreted as past exposure rather than active infection. And yet the fatigue is still there — not the ordinary tired of someone who has been sick and is recovering, but a heavy, unshifting exhaustion that doesn't respond to rest in the way exhaustion should. The joint pain moves. Your thinking is slower than it was. You have moments of tingling or word-finding difficulty that weren't there before the tick bite, or the illness, or whatever the beginning of this was. You went back to your doctor. You were told you'd had Lyme disease, you were treated, the infection is gone, and what you're experiencing now is probably post-infectious. Possibly anxiety. Possibly fibromyalgia. This is the point at which the clinical picture diverges, and the divergence is not merely semantic.
Post-treatment Lyme disease syndrome — PTLDS — is a recognized clinical entity in mainstream medicine. The Centers for Disease Control and the Infectious Diseases Society of America acknowledge that a subset of patients who receive appropriate antibiotic treatment for documented Lyme disease experience persistent symptoms afterward: fatigue, musculoskeletal pain, cognitive symptoms, sleep disturbance. The estimated prevalence is somewhere between 10 and 20 percent of treated patients. The mechanism of PTLDS is not fully established. Competing hypotheses include residual immune dysregulation that outlasts the infection, damage to neurological tissue that persists as functional impairment, autoimmune responses triggered by cross-reactivity between Lyme antigens and self-tissue, and microbiome disruption from antibiotic treatment that affects immune and nervous system function.
"Chronic Lyme disease," as a separate construct, is used by some clinicians and patient communities to refer to an ongoing active infection with Borrelia that persists despite treatment and requires prolonged or repeated antibiotic courses. This construct is not accepted by mainstream infectious disease medicine. Multiple randomized controlled trials of extended antibiotic therapy in PTLDS patients have failed to demonstrate benefit compared to placebo, at the cost of serious antibiotic-related adverse events. The IDSA guidelines explicitly do not recommend long-term antibiotic therapy for PTLDS. This is where the mainstream and functional medicine communities have arrived at a genuine clinical disagreement — not a misunderstanding, not a suppression of data, but a reading of the available evidence that differs between a specialty focused on infection and communities focused on chronic illness and symptom management.
The functional medicine and integrative community's parallel framework takes the persistent symptom picture seriously as a clinical reality regardless of the infection debate. The focus shifts from whether active Borrelia is present to what biological mechanisms are generating the symptoms — immune dysregulation, HPA axis disruption, mitochondrial dysfunction, autonomic nervous system involvement, biotoxin accumulation, and the downstream effects of chronic illness on sleep, nutrition status, and psychological wellbeing. This framework generates a different set of interventions — not antibiotics, but immune support, inflammation management, autonomic regulation, detoxification support, and mitochondrial optimization.
Into this framework, peptides enter the conversation. The honest characterization of the peptide-Lyme evidence base is that it is sparse, largely observational, and comes substantially from clinicians working in chronic illness practices rather than from formal clinical trials. There is no peptide with an established evidence base specifically in PTLDS or chronic Lyme. What exists is biological plausibility, mechanism-based reasoning, and clinical observation. That is a meaningful starting point, not a proven endpoint.
Thymosin Alpha-1 is the most discussed peptide in this context, and the reasoning is coherent. PTLDS involves immune dysregulation — the post-infectious immune state is characterized by cytokine imbalances, altered T-cell subsets, and in some patients evidence of ongoing inflammatory activity without confirmed ongoing infection. Thymosin Alpha-1's immune-modulatory profile — its effects on T-cell maturation, its ability to shift immune responses toward more appropriate regulatory balance, its established use in infectious disease and immune support contexts — makes it a candidate for supporting immune recalibration in the post-treatment picture. It has been used by practitioners working with chronic illness populations including PTLDS patients in observational clinical contexts. It is not FDA-approved for this indication, and clinical trial evidence in PTLDS is not available. The mechanism is plausible; the evidence is clinical-observational rather than controlled.
VIP's relevance in this context is particularly interesting because of its role at the autonomic-immune interface. PTLDS frequently involves symptoms consistent with autonomic nervous system dysfunction — heart rate variability changes, orthostatic intolerance, temperature dysregulation, the kind of autonomic instability that is distinct from classic dysautonomia but consistent with a post-infectious disruption of the autonomic-immune axis. VIP receptors are present on both immune cells and autonomic nervous system structures. VIP's effects include modulation of pro-inflammatory cytokines, support for regulatory T-cell function, and influence on autonomic tone. Some practitioners working with PTLDS and chronic illness populations describe VIP as one of the more clinically interesting peptides in this population, particularly where the autonomic and immune pictures appear linked. This is clinical observation, not controlled trial data.
BPC-157 enters the conversation through its anti-inflammatory and gut-protective effects. Antibiotic treatment, which is the standard therapy for acute Lyme, has documented effects on the gut microbiome that can be substantial and persistent. Dysbiosis following antibiotic courses is common and contributes to downstream immune dysregulation — the gut microbiome is a central regulator of immune tone, and its disruption has systemic consequences. BPC-157's gut mucosal protection and microbiome-supportive effects (through maintenance of intestinal integrity and gut environment) are relevant here. Additionally, the joint and musculoskeletal pain that persists in PTLDS patients may be partly addressable through BPC-157's anti-inflammatory and connective tissue repair effects, based on preclinical data. These are reasonable mechanisms without controlled human data in the PTLDS context.
Glutathione and oxidative stress are part of the chronic Lyme conversation in functional medicine frameworks. Chronic illness, ongoing immune activation, and mitochondrial stress all increase oxidative burden. Glutathione is the body's principal endogenous antioxidant, and depletion is common in chronic illness populations. Intravenous or liposomal glutathione administration is used by practitioners working with chronic Lyme populations as part of detoxification and oxidative stress support. The evidence base for this specific application is clinical-observational. It is a reasonable supportive measure rather than a primary treatment.
The foundational considerations in PTLDS that precede and undergird any peptide conversation are significant. Sleep quality is frequently severely disrupted in this population and is both a symptom and a driver of immune and neurological dysfunction — addressing sleep with appropriate rigor is not peripheral. Nutritional adequacy, particularly B vitamins (including B12), magnesium, zinc, and vitamin D, affects neurological function, energy metabolism, and immune regulation in ways that matter in this context. Stress management is relevant because HPA axis dysregulation is common in post-infectious illness and feeds back into immune and autonomic dysfunction. Evaluation for coinfections — Bartonella, Babesia, Ehrlichia, and others — is clinically important because tick-borne coinfections are not uncommon in patients bitten by ticks and may not resolve with standard Lyme antibiotic courses. Biotoxin exposure and CIRS (chronic inflammatory response syndrome) is a framework developed by some practitioners to explain a subset of chronic illness presentations; its clinical evidence base is contested but some patients with persistent symptoms have benefited from biotoxin-focused evaluation. These considerations belong in a comprehensive clinical assessment.
The case for specialist evaluation in persistent post-treatment symptoms is not about confirming or denying a particular diagnostic framework. It is about ruling out the treatable things — other infections, autoimmune conditions that may have been unmasked by the initial illness, structural neurological findings, sleep disorders, hormonal dysfunction — before attributing the picture to PTLDS and proceeding with a management plan. An infectious disease specialist should be part of the evaluation, particularly to assess for coinfections and evaluate the infection status picture thoroughly. An integrative or functional medicine physician can address the broader chronic illness picture — the immune dysregulation, the autonomic components, the nutritional and mitochondrial support framework, and the question of whether adjunctive approaches including peptides have a role. These two perspectives are not mutually exclusive; the best care for this population draws on both.
If you are experiencing persistent symptoms after Lyme treatment and are not finding adequate answers in standard care, the work ahead involves finding providers who take the post-treatment symptom picture seriously as a clinical entity, who conduct a thorough evaluation of the contributing factors, and who are honest with you about what the evidence supports and what is still being worked out. The peptide conversation in this space is a reasonable one to have with the right clinician. It should be held as an adjunctive consideration, grounded in mechanism and honest about evidence, alongside the foundational work of sleep, nutrition, stress, and comprehensive diagnostic evaluation — not as an alternative to that work, and not as a substitute for the specialist engagement that this clinical picture actually requires.
Frequently asked